KLRS logo

KALARIS THERAPEUTICS INC

KLRSNASDAQ
🏆 #4336 by market capEarnings Nov 10US Equity
$355.18▲ $16.69 (+4.70%)
Simulated price
🔔
Track KLRS
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 4.7%
7d—
14d—
30d—
ytd—
1y—
🏦Market Cap
$64M
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
—
Otter Score
68
Fair
No chart data available for KLRS.

Trading Snapshot

Day Range
$353.47 – $361.96
52-Week Range
$2.91 – $11.88
Volume
$1.82B
Avg Volume
$1.32B
Shares Outstanding
23.8M
Next Earnings
Nov 14, 2026

Fundamentals Snapshot

Annual Revenue
$18M
Last Q Revenue
$4M
P/E Ratio
—
P/S Ratio
—
EPS (TTM)
$-2.09
Dividend Yield
—
Dilution (1yr)
+356.2%

Why Investors Own KLRS

  • ✓High-growth profile — revenue up +14.3% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 53% gross margin and 8% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

KLRS logo

KALARIS THERAPEUTICS INC

KLRS
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$46M▼ −16.5% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$43M▼ −36.2% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
22.9M▲ +356.2% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$97M▼ −$22M YoY
StockOtter · stockotter.space

About KALARIS THERAPEUTICS INC

Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), as well as for the treatment of other exudative and neovascular retinal diseases.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Fair
68/100

Analyst Price Target

ⓘ
Average Target
$441.23
▲ +24.2% Upside
High Target$553.74
Low Target$406.28
Based on 37 analysts

Latest News & Updates

🚀
Barron’s·2h ago

KALARIS THERAPEUTICS INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
Barron’s·5h ago

Analysts lift KLRS price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
Bloomberg·1d ago

KALARIS THERAPEUTICS INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.